Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey - Summary - MDSpire
Advertisement
Testing for Sexually Transmitted and Bloodborne Infections in Substance Users: Insights from the 2023 British Columbia Harm Reduction Client Survey
To investigate factors associated with recent STBBI testing among clients of harm reduction sites in British Columbia, emphasizing the public health implications of these findings.
Key Findings:
High prevalence of STBBIs among people who use substances (PWUS) in BC, with significant barriers to testing, including specific statistics on prevalence rates.
Community-based, low-barrier approaches, such as point-of-care testing at harm reduction sites, can increase testing uptake, supported by data from pilot initiatives.
Stigma, discrimination, and social determinants of health significantly hinder access to STBBI testing for PWUS, highlighting the need for targeted interventions.
Interpretation:
Addressing barriers to STBBI testing through harm reduction services is crucial for early detection and treatment, ultimately reducing STBBI transmission among PWUS, particularly through community engagement.
Limitations:
The study relies on self-reported data, which may be subject to bias.
Findings may not be generalizable beyond the specific harm reduction sites surveyed.
Potential biases in convenience sampling may affect the representativeness of the sample.
Conclusion:
Enhancing STBBI testing access in harm reduction settings is vital for improving health outcomes for PWUS and reducing the burden of STBBIs, with an emphasis on community involvement.
by Amrit Tiwana, Katherine A. Twohig, Mieke Fraser, Brooke Kinniburgh, Charlene Burmeister, Paul Choisil, Elizabeth Haywood, Dylan Griffith, Chloé G. Xavier, Alannah Hannigan, Kate Salters, Sofia R. Bartlett
